How many drugs treat Pyelonephritis?

Drug Landscape tracks 7 marketed treatments for Pyelonephritis (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/pyelonephritis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Pyelonephritis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pyelonephritis (disease) competitive landscape: 7 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

7 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Pyelonephritis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Test formulation (Treatment A)	test-formulation-treatment-a	Pfizer	Enzyme inhibitor	Specific enzyme	Not yet determined
Recarbrio	RELEBACTAM	Merck & Co.	Renal Dehydropeptidase Inhibitor [EPC]		2019-01-01
Fetroja	CEFIDEROCOL	Shionogi	Cephalosporin Antibacterial		2019-01-01
Avycaz	AVIBACTAM	Cerexa Inc	beta Lactamase Inhibitor [EPC]		2015-01-01
Doribax	DORIPENEM	Shionogi	Penem Antibacterial		2007-01-01
Levaquin	levofloxacin	Generic (originally Daiichi Sankyo/J&J)	Fluoroquinolone Antibacterial [EPC]	CAAX prenyl protease 2, Multidrug and toxin extrusion protein 1, Potassium voltage-gated channel subfamily H member 2	1996-12-20
Ofloxacine	Ofloxacine	Assistance Publique - Hôpitaux de Paris		Gamma-aminobutyric acid receptor subunit alpha-2, Histamine H3 receptor, Muscarinic acetylcholine receptor M1

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 2 drugs in Pyelonephritis
Shionogi · 2 drugs in Pyelonephritis
Cerexa Inc · 1 drug in Pyelonephritis
Merck & Co. · 1 drug in Pyelonephritis
Pfizer · 1 drug in Pyelonephritis
Generic (originally Daiichi Sankyo/J&J) · 1 drug in Pyelonephritis
Assistance Publique - Hôpitaux de Paris · 1 drug in Pyelonephritis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Pyelonephritis:

Cite this brief

Drug Landscape (2026). Pyelonephritis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/pyelonephritis. Accessed 2026-06-10.

Pyelonephritis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing